Medicare Part B suppliers may deliver the initial immunosuppressive drugs prescribed to a beneficiary after a transplant procedure to an address other than their home to ensure timely access to the medications at discharge, the Centers for Medicare & Medicaid Services announced last week in updated guidance. “In certain cases, a beneficiary who has received a transplant does not return home immediately after discharge,” the guidance states. “In order to ensure timely beneficiary access to prescribed immunosuppressive medications at the time of discharge, suppliers may deliver the initial prescriptions of a beneficiary’s immunosuppressive drugs to an alternate address, such as the transplant facility or alternative location where the beneficiary is temporarily staying, for example, temporary housing, instead of delivering the drugs to the patient’s home address.” AHA advocated for the policy change.

Related News Articles

Headline
The Medicare Payment Advisory Commission Friday released its March report to Congress.
Perspective
As our country works to expand health coverage and improve access to care, “Medicare for All” is getting a lot of attention. There are many different flavors…
Headline
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive…
Headline
Creating a government-run, Medicare-like option on the individual health insurance exchanges could negatively affect patient access to care and reduce hospital…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on the president’s fiscal year 2020 budget request for the Department of Health and…
Headline
President Trump today submitted to Congress his budget request for fiscal year 2020.